+467.0%
MRNA vs AVAV
-39.3%
+506.3%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | AVAV | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.4% | -0.2% | +5.6% | +5.4% |
| 7D | -1.1% | +1.4% | -2.5% | -1.4% |
| 30D | +126.1% | -24.3% | +150.4% | +139.9% |
| 3M | +190.0% | -20.1% | +210.2% | +202.3% |
| 6M | +157.2% | -29.4% | +186.6% | +171.9% |
| YTD | +388.2% | -39.3% | +427.5% | +396.0% |
| 1Y | +467.0% | -39.3% | +506.4% | +341.5% |
| All | +467.0% | -39.3% | +506.3% | +341.5% |
Cumulative growth
Daily Returns
Daily percentage return beside AVAV.
Daily Out/Under-Performance
Portfolio return minus AVAV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × AVAV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded AVAV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling